Accelerate discovery. Reduce risk. Improve outcomes.
Evokera, powered by Sentinus.AI®, turns biological complexity into actionable intelligence — helping partners identify better targets, design smarter therapies, discover biomarkers, evaluate assets, and accelerate translational decisions across the healthcare innovation lifecycle.
AI-powered lead molecule discovery for therapeutics, diagnostics, infectious disease, and high-value biologics programs — designed computationally first, validated experimentally second.
IP/AI Platform Architecture
Proven against SARS-CoV-2 during the COVID-19 pandemic.
Evokera’s scientific founder, Dr. Lurong Pan, led the AI-driven design of broad, mutation-resistant neutralizing antibodies against more than 1,300 SARS-CoV-2 strains. Seventy AI-designed antibodies were experimentally validated in binding and live-virus neutralization assays — active against wild-type, Delta, and Omicron strains — achieving up to 269-fold improvements in binding affinity over their templates, all designed from sequence alone without animal immunization or 3D crystal structures. The work was peer-reviewed and published open access in Nature’s Scientific Reports, and the platform’s pandemic-preparedness program has been recognized with the Merck Pandemic Preparedness Award and supported by a Bill & Melinda Gates Foundation grant.
Healthcare innovators do not need more data. They need better decisions.
Drug companies spend billions per approved drug and still face high failure rates. The old model guesses at molecular design, then tests thousands of candidates in expensive wet labs. The new model designs computationally first, then validates experimentally.
Discovery is too slow and too expensive.
Programs fail late because targets, molecules, biomarkers, and translational assumptions are not validated early enough.
Faster, evidence-based prioritization.
Teams need unified intelligence to identify better targets, reduce false starts, and focus resources on the highest-value opportunities.
Higher confidence before committing capital.
Partners want stronger scientific conviction, shorter timelines, reduced risk, and a clearer path to clinical and commercial impact.
Not theoretical. Revenue-generating, validated, and moving into the clinic.
The integrated SentinusAI® engine has supported validated projects across disease areas, active fee-for-service contracts, and a Phase I asset designed with the platform.
Strategic validation
Featured scientific foundation model, Gates Foundation support, and Merck Pandemic Preparedness recognition.
Commercial traction
20+ active fee-for-service contracts and collaborations with leading pharma, academic, and biotechnology organizations.
An integrated AI discovery and decision-support engine.
AINN-P1 Foundation Model
A proprietary 1B-parameter protein foundation model, built on 20+ years of computational chemistry and AI research, that reads the language of proteins and helps design entirely new molecules from sequence alone.
Screen billions. Validate faster.
Designed to screen 10 billion antibody sequences in hours, with no animal testing or 3D crystal structure required for initial design.
Data Integration
Scientific, clinical, genomic, literature, and market signals.
Target Intelligence
Target discovery, validation, prioritization, and risk scoring.
Molecule Design
AI-assisted biologics, antibodies, small molecules, and drug assets.
Diagnostic Insight
Biomarkers, companion diagnostics, and patient stratification.
Translational Strategy
Decision support from hypothesis to development pathway.
Solutions for discovery, diagnostics, and asset development.
Target Rx™
AI-designed first-in-class biological drug targets in 1–2 months, supported by 500+ validated targets and strong wet-lab performance.
Target Dx™
Diagnostic solutions that identify likely responders before first prescription, especially in oncology, precision medicine, and GLP-1 programs.
Revive Rx™
Rescue intelligence for failed Phase I/II drugs, targeting new value from written-off or stalled assets.
Infectious Rx Assets
License-ready biologics for pandemic response and infectious disease programs.
BioDrugs Rx Assets
Phase I-validated biologic assets ready for out-licensing, including the IL-13 × TSLP bispecific lead asset.
Built for teams that need better scientific decisions faster.
Biopharma
Faster discovery, stronger targets, lower R&D risk.
Diagnostics
Biomarker discovery and companion diagnostic strategy.
Research Institutions
Advanced AI capabilities and translational insight.
Precision intelligence across high-impact diseases.
AI is not the outcome. Better decisions are.
Partners want better programs, fewer failures, faster timelines, stronger returns, and solutions that reach patients.
From prediction to translational confidence.
Evokera combines AI-powered intelligence with biological expertise, platform products, IP strategy, and development insight.
From computation to Phase I.
The platform has produced high-affinity candidates across multiple targets, including SARS-CoV-2, CD19, IL-15, TSLP, and His-tag benchmarks. The IL-13 × TSLP bispecific has advanced to Phase I clinical trial.
Sequence-only design
Design antibodies from sequence alone without requiring animal immunization or 3D crystal structures.
Genome-scale efficiency
Built for broad screening across entire genomes and difficult or previously undruggable targets.
Enterprise security
AWS-hosted project environments and regional cloud deployment options for data residency needs.
Scientific, commercial, and financial leadership for platform execution.
Dr. Lurong Pan
CEO & Founder. Computational chemistry, AI, therapeutic design, global health innovation, and 100+ publications.
David Donaldson
CFO. Oxford University, FCA, 20+ years investment banking, sovereign investment authority experience, and company-building across the Middle East.
Dr. Rita Boukamel
CCO. 25+ years in diagnostics and healthcare commercialization with CDx go-to-market and regulatory expertise.
A revenue-generating platform with a clinical-stage asset.
Evokera is not a single-program bet. It is a commercial, AI-powered platform business with validated science, active customer revenue, and a Phase I asset already in human dosing. We partner with investors aligned with long-term value creation in AI-native healthcare.
Multiple shots on goal, not one binary outcome.
Our offerings span discovery, diagnostics, asset rescue, and out-licensing — diversifying value across the portfolio rather than resting on a single clinical event.
Proven, IP-protected, and ready to scale.
Multiple revenue lines, a defensible IP position, and a validated platform position Evokera for durable growth across the healthcare innovation lifecycle.
Ready to accelerate your next discovery decision?
Connect with us to explore AI-powered discovery, diagnostics, asset evaluation, out-licensing, and strategic partnership opportunities.